All News

It's time for some good-natured holiday health care gift-giving and we did some window shopping for you. Take a moment, take a breath, and scroll through 10 potential winners.

Statin use remained at only 35% among eligible adults since updated guidelines from ACC/AHA on cholesterol treatment.

The 10 most important take-homes from the 2023 ACC/AHA AF guidelines are summarized in this Guideline Topline, an at-a-glance preview for primary care.

Camouflaging e-cigarettes as kid- and teen-appealing drinks and toys may help youth conceal the products from adults, increase risk of harm to children.

Your daily dose of the clinical news you may have missed.

The coadministration of RSVpreF and seasonal influenza vaccine was found to generate robust immune responses in older adults, reported authors of new study.

Reducing stigma associated with chronic liver disease and expediting diagnosis and referral will take some time but progress is being made, Luxon says.

Transplant hepatologist Dr Bruce Luxon says primary care is essential to making progress against chronic liver disease but doesn't have the resources it needs.

The risk of cardiovascular disease increased with longer cumulative exposure to ADHD medications, peaking at 3 to 5 years of use, reported researchers.

With the holiday season in full swing, you will want to remind your patients of these 4 hazardous holiday food and drug interactions. 

The revised guidance classifies AF into 4 stages, emphasizes prevention and aggressive rhythm control, and upgrades recommendations for catheter ablation and LAA occlusion.

Cluster headache is rare and can be disabling. It can be misdiagnosed, particularly as migraine, but treatments are very different. Learn more in a short slide show.

Which antihypertensive therapy options are most and least effective for patients with migraine? Get details, here.

Your daily dose of the clinical news you may have missed.

Identifying women at risk for preeclampsia with severe features and the most effective treatment is essential to reduce morbidity as well as to contain costs.

The 5 leading advocacy groups said the safety of people with obesity is at risk and called on the FDA to change clinical trial inclusion requirements and expedite labeling changes.

Arun Jesudian, MD, details key findings from a study he recently presented at The Liver Meeting 2023.

Your daily dose of the clinical news you may have missed.